EurekaMag.com logo
+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow



Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow



Haematologica 92(5): 605-611



Background and ObjectivesTo date, bone marrow (BM) is the most common source of cells to use in order to assess minimal residual disease (MRD) in acute myeloid leukemia (AML). In the present study, we investigated whether peripheral blood (PB) could be an alternative source of cells for monitoring MRD in AML.Design and MethodsFifty patients with AML were monitored for MRD after the achievement of complete remission. Using multiparametric flow cytometry we compared the levels of MRD in 50 and 48 pairs of BM and PB after induction and consolidation, respectively.ResultsAfter induction and consolidation therapy, the findings in BM and PB were significantly concordant (r=0.86 and 0.82, respectively, p < 0.001 for both comparisons). The cut-off value of residual leukemic cells in PB which correlated with outcome was 1.5x10(-4). Thirty-three of 43 (77%) patients with > 1.5x10(-4) residual leukemic cells in PB after induction had a relapse, whereas the seven patients with lower levels did not (p=0.0002). After consolidation, 38 patients had a level of MRD > 1.5x10-4 and 31 (82%) had a relapse; nine out of the remaining ten patients, whose levels of MRD were below 1.5x10(-4), are still relapse-free (p=0.00006). In multivariate analysis, PB MRD status at the end of consolidation was found to have a significant effect on relapse-free survival (p=0.036).Interpretation and ConclusionsThese preliminary results indicate that: (i) PB evaluation can integrate BM assessment for MRD detection in patients with AML; (ii) PB MRD status at the end of consolidation therapy may provide useful prognostic information.

(PDF emailed within 0-6 h: $19.90)

Accession: 013763446

Download citation: RISBibTeXText

PMID: 17488683

DOI: 10.3324/haematol.10432



Related references

Evaluation of WT1 expression in bone marrow vs peripheral blood samples of children with acute myeloid leukemia—impact on minimal residual disease detection. Leukemia 27(5): 1194-1196, 2013

Minimal residual disease diagnostics in patients with acute myeloid leukemia in the post-transplant period: comparison of peripheral blood and bone marrow analysis. Leukemia & Lymphoma 51(10): 1837-1843, 2011

Detection of minimal residual disease in peripheral blood stem cells from two acute myeloid leukemia patients with trisomy 8 predicts early relapse after autologous bone marrow transplantation. Cancer Genetics & Cytogenetics 133(1): 98-101, February, 2002

Monitoring minimal residual disease in patients with MLL-AF6 fusion transcript-positive acute myeloid leukemia following allogeneic bone marrow transplantation. International Journal of Hematology 75(3): 298-301, April, 2002

WT1 mRNA level in peripheral blood is a sensitive biomarker for monitoring minimal residual disease in acute myeloid leukemia. Tohoku Journal of Experimental Medicine 219(2): 169-176, 2009

Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression. Experimental and Therapeutic Medicine 3(1): 129-133, 2012

Comparative analysis of minimal residual disease in peripheral blood versus bone marrow in childhood acute lymphoblastic leukemia. Blood 98(11 Part 1): 841a-842a, November 16, 2001

Detection of minimal residual disease (MRD) in bone marrow (BM) and peripheral blood (PB) in childhood acute lymphoblastic leukemia (ALL) by flow cytometry (FC). Journal of Clinical Oncology 23(16_suppl): 8544-8544, 2016

Potential of antisense oligomers to bcl-2 for purging of minimal residual disease in bone marrow and peripheral blood stem cell harvests in acute myeloid leukaemia. British Journal of Haematology 97(SUPPL 1): 58, 1997

Increased myeloid precursors in regenerating bone marrow; implications for detection of minimal residual disease in acute myeloid leukemia. Neoplasma 54(6): 471-477, 2007

Quantitative monitoring of WT1 expression in peripheral blood before and after allogeneic stem cell transplantation for acute myeloid leukemia - a useful tool for early detection of minimal residual disease. Neoplasma 60(1): 74-82, 2013

Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL. Leukemia (Basingstoke) 16(8): 1432-1436, 2002

Successful donor leukocyte transfusion at molecular relapse for a patient with acute myeloid leukemia who was treated with allogeneic bone marrow transplantation: Importance of the monitoring of minimal residual disease by WT1 assay. Bone Marrow Transplantation 21(5): 525-527, March 1, 1998

Clinical relevance of minimal residual disease monitoring in adult patients with acute myeloid leukemia. Blood 98(11 Part 1): 580a, November 16, 2001

Minimal residual disease monitoring based on FLT3 internal tandem duplication in adult acute myeloid leukemia. Leukemia Research 36(3): 316-323, 2012